Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Docetaxel
65%
Toxicity
53%
Paclitaxel
46%
Tamoxifen
38%
Drug
34%
Therapeutic Drug Monitoring
29%
Malignant Neoplasm
28%
Adverse Event
28%
Erlotinib
26%
Breast Cancer
24%
Neoplasm
21%
Chemotherapy
21%
Sorafenib
20%
Diseases
20%
Overall Survival
20%
Duragesic
19%
Endoxifen
19%
Non Small Cell Lung Cancer
18%
CYP2D6
17%
Pemetrexed
17%
Nivolumab
17%
Ritonavir
15%
Phosphotransferase Inhibitor
15%
Progression Free Survival
14%
Monotherapy
14%
Irinotecan
13%
Actinium 225
12%
Gemcitabine
11%
Osimertinib
11%
Anticarcinogen
10%
Palbociclib
10%
Hemodialysis
10%
Diabetes Mellitus
10%
P-Glycoprotein
10%
Taxane
10%
High Performance Liquid Chromatography
10%
CYP3A4
9%
Pembrolizumab
9%
Enzyme
9%
Elimination
9%
Immune Checkpoint Inhibitor
9%
C Peptide
9%
Clinical Trial
9%
Melanoma
8%
Ribociclib
8%
Protein Tyrosine Kinase Inhibitor
8%
Intraperitoneal Chemotherapy
8%
Cmin
8%
Neutropenia
8%
Medicine and Dentistry
Patient
80%
Therapeutic Procedure
34%
Overall Survival
19%
Inpatient
19%
Toxicity
18%
Progression Free Survival
18%
Chemotherapy
16%
Immune Checkpoint Inhibitor
16%
Combination Therapy
14%
Non Small Cell Lung Cancer
13%
Tamoxifen
13%
Pharmacokinetics
12%
Pemetrexed
11%
Plasma
9%
Serum
9%
C-Peptide
9%
Neoplasm
8%
Therapeutic Drug Monitoring
7%
Nivolumab
7%
Cytoreductive Surgery
7%
Hyperthermic Intraperitoneal Chemotherapy
7%
Cells
6%
Irinotecan
6%
Androgen Receptor
6%
Isocitrate Dehydrogenase
6%
Protein Restriction
6%
Skeletal Muscle
6%
Peptide Receptor
6%
Radionuclide Therapy
6%
Cytotoxic T-Cell
6%
Floxuridine
6%
Diabetes
6%
Paclitaxel
6%
Adverse Event
6%
Side Effect
6%
Blood
5%
Thyroid Antibody
5%
Caloric Restriction
5%
Metastatic Melanoma
5%
Hazard Ratio
5%
T Cell
5%
Breast Cancer
5%
Association
5%
Endoxifen
5%
Diseases
5%
Biochemistry, Genetics and Molecular Biology
CYP2D6
21%
Accuracy
18%
Dose
16%
Sample
16%
Overall Survival
15%
Progression Free Survival
14%
Solution and Solubility
11%
Pharmacokinetics
11%
Blood Level
10%
Association
10%
Kinase
9%
Small Molecule
9%
Phenotype
9%
Single-Nucleotide Polymorphism
9%
Erlotinib
9%
C-Peptide
9%
Development
9%
Mutation
9%
Metabolic Pathway
8%
Steady State
7%
Collagen
6%
Time
6%
Electric Potential
6%
Sunitinib
6%
Isocitrate Dehydrogenase
6%
Liquid
6%
Vascular Endothelial Growth Factor
6%
Attenuation
6%
Prospective Study
6%
Afatinib
6%
Morphine-6-Glucuronide
6%
Morphine-3-Glucuronide
6%
Hydromorphone
6%
Fentanyl
6%
Granzyme B
6%
pH
6%
Epidermal Growth Factor Receptor
6%
Dried Blood Spot
5%
Germline
5%
Genotyping
5%
